NAD+

The research profile.

Nicotinamide adenine dinucleotide (NAD+) is a pyridine dinucleotide present in every cell, where it serves as the hydride acceptor for the redox reactions of glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. Beyond that classical redox role, it is the obligatory co-substrate for three families of NAD+-consuming enzymes — the sirtuins, the poly(ADP-ribose) polymerases, and the CD38/CD157 ectoenzymes — which cleave the molecule and therefore draw continuously on the cellular pool.

Because consumption and synthesis run in parallel, tissue NAD+ concentration is treated in the literature as a dynamic set point rather than a fixed quantity. Reviews describe a gradual decline in tissue and cellular NAD+ across ageing in multiple model organisms, attributed in part to rising CD38 activity in senescent-cell-associated macrophages and in part to reduced salvage-pathway flux. This observation is what motivates the large body of work on precursor and direct-NAD+ administration.

Pharmacokinetic work in humans is comparatively sparse. A pilot study tracking the plasma and urine NAD+ metabolome during a six-hour intravenous infusion reported no measurable change in plasma NAD+ or its metabolites until after the two-hour mark, with the majority of administered material appearing in urine as metabolites — a finding frequently cited when comparing direct NAD+ administration against oral precursor strategies.

For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.

Categorised as Performance — Mitochondrial and cellular-energy research compounds.